This could be INSM next week - another very recent Phase 2 "success" story
They MET their primary endpoint which is deemed a success for their trail (Friday) so.......
3/21/2014 4:42 PM ET
Endocyte Inc. (ECYT: Quote) announced Friday morning that its Phase 2b TARGET trial met the primary endpoint for the combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer patients.
Endocyte gapped open dramatically higher Friday morning, but gave back some ground during the first hour of trade, before settling into a range. The stock closed up by 13.53 at $28.17 on the highest volume of the year.